Critically DTP reduced CD103+ dendritic cell (DC) populations in the tumor microenvironment which accounted for resistance to combination anti-CTLA-4 and anti-PD1 antibodies after progression of the targeted therapy triplet [16]. The gene discussed is PDCD1; the disease is neoplasm.